• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[胰岛素依赖型糖尿病患者凝血与纤溶的选定参数及其与糖尿病控制水平的关系]

[Selected parameters of blood coagulation and fibrinolysis and their relationship to the level of diabetes control in patients with insulin-dependent diabetes mellitus].

作者信息

Majkowska L, Mamos E, Fuchs H, Pynka S, Jastrzebska M, Krzyzanowska B, Czekalski S

机构信息

Klinika Endokrynologii i Chorób Przemiany Materii PAM, Szezecin.

出版信息

Pol Arch Med Wewn. 1994 Aug;92(2):147-53.

PMID:7800583
Abstract

The aim of the study was to evaluate plasma concentration of fibrinogen, plasma activity of antithrombin III (AT-III) and plasma activity of plasminogen activator inhibitor (PAI-I) in insulin-dependent diabetic (IDDM) patients and the assessment of correlation between them and the parameters of glyco-metabolic control comprising glycemia and concentrations of fructosamine and glycated hemoglobin HbA1c. Eighteen IDDM patients (mean age 28.3 +/- 11.3 ys, mean duration of disease 12.2 +/- 5.3 ys) without over nephropathy and without macroangiopathy were investigated. Control group consisted of 8 healthy subjects. Plasma fibrinogen concentrations were similar in IDDM patients and in controls (3.54 +/- 0.45 g/l and 3.31 +/- 0.54 g/l respectively). Plasma activity of AT-III in diabetic patients (90.6 +/- 22.4%) was similar to that in healthy subjects (94.6 +/- 25.0%). Fibrinogen concentrations and AT-III activities showed no correlation with glycemia and concentrations of fructosamine and HbA1c. Plasma activity of PAI-I was significantly lower in diabetics than in controls (respectively 1.56 +/- 0.72 U/ml and 2.75 +/- 1.25 U/ml, p < 0.005). PAI-I activity correlated negatively with fasting blood glucose (p < 0.05) but did not correlate with concentrations of fructosamine or HbA1c. The results suggest that glycemic control in diabetic patients do not influence on concentrations of fibrinogen and activity of AT-III but diminished activity of PAI-I is related to hyperglycemia.

摘要

本研究旨在评估胰岛素依赖型糖尿病(IDDM)患者的血浆纤维蛋白原浓度、抗凝血酶III(AT-III)的血浆活性以及纤溶酶原激活物抑制剂(PAI-I)的血浆活性,并评估它们与包括血糖、果糖胺浓度和糖化血红蛋白HbA1c在内的糖代谢控制参数之间的相关性。对18例无肾病和大血管病变的IDDM患者(平均年龄28.3±11.3岁,平均病程12.2±5.3年)进行了研究。对照组由8名健康受试者组成。IDDM患者和对照组的血浆纤维蛋白原浓度相似(分别为3.54±0.45 g/l和3.31±0.54 g/l)。糖尿病患者的AT-III血浆活性(90.6±22.4%)与健康受试者相似(94.6±25.0%)。纤维蛋白原浓度和AT-III活性与血糖、果糖胺浓度和HbA1c均无相关性。糖尿病患者的PAI-I血浆活性显著低于对照组(分别为1.56±0.72 U/ml和2.75±1.25 U/ml,p<0.005)。PAI-I活性与空腹血糖呈负相关(p<0.05),但与果糖胺或HbA1c浓度无关。结果表明,糖尿病患者的血糖控制对纤维蛋白原浓度和AT-III活性无影响,但PAI-I活性降低与高血糖有关。

相似文献

1
[Selected parameters of blood coagulation and fibrinolysis and their relationship to the level of diabetes control in patients with insulin-dependent diabetes mellitus].[胰岛素依赖型糖尿病患者凝血与纤溶的选定参数及其与糖尿病控制水平的关系]
Pol Arch Med Wewn. 1994 Aug;92(2):147-53.
2
Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.胰岛素依赖型糖尿病患者的凝血与纤溶系统损害
Thromb Res. 1992 Sep 15;67(6):643-54. doi: 10.1016/0049-3848(92)90068-l.
3
[Some parameters of hemostasis and fibrinolysis in diabetic patients].[糖尿病患者止血与纤溶的一些参数]
Pol Arch Med Wewn. 1998 Aug;100(2):133-8.
4
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.亚临床甲状腺疾病中的血液凝固、纤溶活性和血脂谱:亚临床甲状腺功能亢进会增加血浆凝血因子X活性。
Clin Endocrinol (Oxf). 2006 Mar;64(3):323-9. doi: 10.1111/j.1365-2265.2006.02464.x.
5
Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.与配对的血糖正常的同胞相比,II型(非胰岛素依赖型)糖尿病患者的高血糖同胞具有更高的纤溶酶原激活物抑制剂-1水平、中心性肥胖和胰岛素抵抗。
Diabetologia. 2002 May;45(5):635-41. doi: 10.1007/s00125-002-0795-8. Epub 2002 Apr 26.
6
[Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].[1型和2型糖尿病患者血液中组织型纤溶酶原激活物(T-PA)、其抑制剂(PAI-1)和纤维蛋白原的水平]
Cas Lek Cesk. 1996 Mar 20;135(6):174-7.
7
Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.伴有和不伴有糖尿病血管并发症的2型糖尿病患者的凝血和纤维蛋白溶解参数。
Med Princ Pract. 2005 Jan-Feb;14(1):22-30. doi: 10.1159/000081919.
8
Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.口服避孕甾体激素对动脉血栓形成生化标志物的药效学作用。非糖尿病女性和胰岛素依赖型糖尿病女性的研究。
Dan Med Bull. 2002 Feb;49(1):43-60.
9
Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.短期代谢控制改善血糖控制不佳的住院2型糖尿病患者的纤维蛋白溶解:与纤溶酶原激活物抑制剂1降低相关
Exp Clin Endocrinol Diabetes. 2004 Apr;112(4):175-80. doi: 10.1055/s-2004-817965.
10
[Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].[闭塞性动脉粥样硬化症和糖尿病大血管病变患者的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及其他纤溶参数]
Pol Merkur Lekarski. 2001 Nov;11(65):414-7.